← Back to Search

Cytokine

Interleukin-2 for Melanoma

Phase 2
Waitlist Available
Research Sponsored by Blumenthal Cancer Center at Carolinas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No involvement of the CNS or a major nerve
Renal: Creatinine normal
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well interleukin-2 works in treating patients with metastatic melanoma.

Who is the study for?
This trial is for adults over 18 with metastatic melanoma, a type of skin cancer that has spread. Participants must not be pregnant or nursing and should use effective contraception if fertile. They need normal liver and kidney function, no systemic infections, HIV, CNS involvement, ongoing bleeding, or severe psychiatric disease. Prior treatment for melanoma must have been at least 28 days ago.Check my eligibility
What is being tested?
The trial is testing the effectiveness of Interleukin-2 in treating metastatic melanoma. It's a Phase II study which means it focuses on how well the treatment works and further evaluates its safety.See study design
What are the potential side effects?
Interleukin-2 can cause flu-like symptoms such as fever and chills, fatigue, nausea and vomiting. It may also lead to low blood pressure or affect organ functions like those of the heart or kidneys.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has not spread to my brain or major nerves.
Select...
My kidney function, measured by creatinine, is normal.
Select...
I do not have an infection that affects my whole body.
Select...
My melanoma has spread and was confirmed by a biopsy.
Select...
My liver function, specifically bilirubin, is normal.
Select...
I am over 50 or have heart issues but passed my cardiac stress test.
Select...
My lung function is above 65% of what's expected for someone my age and size.
Select...
I do not have any current bleeding.
Select...
I am 18 years old or older.
Select...
My cancer can be measured by tests.
Select...
I am mostly independent and active.
Select...
I am a woman of childbearing age and my pregnancy test is negative.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Blumenthal Cancer Center at Carolinas Medical CenterLead Sponsor
3 Previous Clinical Trials
28 Total Patients Enrolled
Richard L. White, MDStudy ChairBlumenthal Cancer Center at Carolinas Medical Center
3 Previous Clinical Trials
28 Total Patients Enrolled

Media Library

Interleukin-2 (Cytokine) Clinical Trial Eligibility Overview. Trial Name: NCT00002845 — Phase 2
Skin Cancer Research Study Groups:
Skin Cancer Clinical Trial 2023: Interleukin-2 Highlights & Side Effects. Trial Name: NCT00002845 — Phase 2
Interleukin-2 (Cytokine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002845 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being recruited for this research?

"This particular trial, which was originally posted on September 1st 1995, is unfortunately not currently looking for new candidates. However, as of right now there are 789 other trials that are still recruiting patients."

Answered by AI

Is this medication regimen associated with a high risk of adverse effects?

"The safety of this treatment was scored a 2 by our team at Power. This is due to the lack of clinical data supporting efficacy, despite some evidence pointing to its safety."

Answered by AI
~1 spots leftby Mar 2025